Pharnext’s Combination Alzheimer’s Therapy shows Synergistic Effects in Mice Models

Pharnext’s Combination Alzheimer’s Therapy shows Synergistic Effects in Mice Models
Pharnext, a biopharmaceutical company that develops therapeutics called pleodrugs that simultaneously target multiple key disease pathways for serious orphan and common neurological diseases, recently announced the pre-clinical findings of their ongoing Phase 2 clinical trial designed to examine the efficacy and safety profile of on of their pipeline pleodrugs, called PXT-864, for the treatment of Alzheimer’s disease. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by neuronal deficits in memory leading to cognitive degeneration in thinking, memory, personality and behavior disorders. Alzheimer’s develops with age and symptoms gradually worsen over several years, ultimately leading to death. Estimates show that approximately 25 million people worldwide are affected by the disorder. At the moment, Alzheimer's disease has no cure and current existing therapies have been shown to provide only temporary and symptomatic modest improvements. In the article reporting the pre-clinical results, entitled “Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy”, recently published in
Subscribe or to access all post and page content.